Safety and Efficacy Study of BCD-066 Compared to Aranesp® for Anemia Treatment in Chronic Kidney Disease Patients
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 196 participants.
Also called NCT02506868
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 196 participants
- Sponsor
- Registry
-
NCT02506868
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Russia
- Registry status
- Completed
Technical summary
Registry record NCT02506868. Randomized; quadruple masking; primary purpose treatment. Start 2015-08-08 (actual); primary completion 2017-01-08 (actual). Results posted on 2019-05-30.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety and Efficacy Study of BCD-066 Compared to Aranesp® for Anemia Treatment in Chronic Kidney Disease Patients
- Condition
- Chronic Kidney Disease
- Condition
- End Stage Renal Failure on Dialysis
- Condition
- Anemia
- Intervention (Drug)
- Darbepoetin alfa
- Lead sponsor
- Biocad
Record details
- Record id
cardio:ct-nct02506868- Content hash
bf155d0f7a4590209f537e79de8aa2f9800f5b1d3adb9c0d031349a7f1449837